Glaukos (NYSE: GKOS) delivers 32% 2025 growth and guides $600–$620M sales
Rhea-AI Filing Summary
Glaukos Corporation reported record results for the fourth quarter and full year 2025, driven by strong uptake of its glaucoma and corneal therapies. Fourth quarter net sales were $143.1 million, up 36% year over year, while full-year 2025 net sales reached $507.4 million, an increase of 32%.
Despite this growth, Glaukos posted a 2025 GAAP net loss of $187.7 million (or $3.28 per share), widened largely by a one-time, non‑cash impairment charge of $112.9 million tied to an acquired intangible asset from the Avedro acquisition as Photrexa transitions to Epioxa. On a non‑GAAP basis, full‑year net loss narrowed to $51.7 million (or $0.90 per share) from $98.3 million in 2024 as operating performance improved.
Non‑GAAP gross margin improved to about 85% in Q4 2025 and 84% for the year. The company ended 2025 with $282.6 million in cash, cash equivalents, short‑term investments and restricted cash and reported no debt. For 2026, Glaukos expects net sales between $600 million and $620 million, reflecting continued momentum from iDose TR and its broader ophthalmic pipeline.
Positive
- Robust revenue growth and higher guidance: 2025 net sales grew 32% to $507.4 million, Q4 sales rose 36% to $143.1 million, and Glaukos issued 2026 net sales guidance of $600–$620 million, signaling expectations for continued strong demand.
- Improving underlying profitability and strong balance sheet: Non-GAAP net loss narrowed to $51.7 million from $98.3 million in 2024, non-GAAP gross margin reached ~84%, and the company ended 2025 with $282.6 million in cash, cash equivalents, short-term investments and restricted cash and no debt.
Negative
- Large GAAP loss driven by impairment: 2025 GAAP net loss widened to $187.7 million, including a one-time, non-cash $112.9 million impairment of an acquired intangible asset related to the Avedro acquisition and the Photrexa to Epioxa transition.
- Operating expenses rising with growth investments: GAAP SG&A and R&D together increased to $482.4 million in 2025 from $411.8 million in 2024, reflecting heavier commercial and development spending while the company remains loss-making on both a GAAP and non-GAAP basis.
Insights
Strong revenue growth and guidance, but GAAP losses remain sizable due to an impairment.
Glaukos is showing rapid top-line expansion. Q4 2025 net sales rose 36% to
Profitability is mixed. A one-time, non-cash impairment of
Balance sheet quality and outlook are notable. The company ended
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| | |||
(State or other jurisdiction | (Commission | (I.R.S. Employer | ||
of incorporation) | File Number) | Identification No.) |
| ||
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code: (
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class: | | Trading Symbol | | Name of each exchange on which registered: |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On February 17, 2026, Glaukos Corporation (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as shall be expressly set forth by specific reference in such filing.
Item 7.01. Regulation FD Disclosure.
A Quarterly Summary containing supplemental business and financial information for the Company’s fourth quarter and fiscal year ended December 31, 2025 is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein. A copy of the Quarterly Summary is also available in the “Financials & Filings” section of the Company’s investor relations website at https://investors.glaukos.com.
The information contained in this Item 7.01 and in the accompanying Exhibit 99.2 shall not be deemed filed for purposes of Section 18 of the Exchange Act, or incorporated by reference in any filing under the Exchange Act or the Securities Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | | Description |
99.1 |
| Press Release of Glaukos Corporation, dated February 17, 2026 |
99.2 | Quarterly Summary of Glaukos Corporation for the fourth quarter and fiscal year ended December 31, 2025 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GLAUKOS CORPORATION | ||
| By: | /s/ Alex R. Thurman | |
|
| Name: | Alex R. Thurman |
|
| Title: | Senior Vice President & Chief Financial Officer |
Date: February 17, 2026
Exhibit 99.1
FOR IMMEDIATE RELEASE
Contact:
Chris Lewis
Vice President, Investor Relations & Corporate Affairs
(949) 481-0510
clewis@glaukos.com
Glaukos Announces Fourth Quarter and Full Year 2025 Financial Results
Aliso Viejo, CA – February 17, 2026 – Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025. Key highlights include:
| ● | Record net sales of $143.1 million in Q4 2025 increased 36% year-over-year on a reported basis and 34% year-over-year on a constant currency basis. |
| ● | Glaucoma record net sales of $119.2 million in Q4 2025 increased 42% year-over-year. |
| ● | U.S. Glaucoma record net sales of $86.4 million in Q4 2025 increased 53% year-over-year. |
| ● | Net sales of $507.4 million in 2025 increased 32% year-over-year. |
| ● | Reaffirmed 2026 net sales guidance of $600 million to $620 million. |
“Our record fourth quarter results cap off a highly successful year of global execution across our key commercial and development initiatives, leaving us well positioned to sustain our strong growth momentum in 2026 and beyond driven by two transformational growth drivers in iDose TR and now Epioxa,” said Thomas Burns, Glaukos chairman and chief executive officer. “We continue to successfully advance our robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.”
Fourth Quarter 2025 Financial Results
Net sales in the fourth quarter of 2025 of $143.1 million increased 36% on a reported basis, or 34% on a constant currency basis, compared to $105.5 million in the same period in 2024.
Gross margin for the fourth quarter of 2025 was approximately (1%), compared to approximately 73% in the same period in 2024. Non-GAAP gross margin for the fourth quarter of 2025 was approximately 85%, compared to approximately 82% in the same period in 2024.
Selling, general and administrative (SG&A) expenses for the fourth quarter of 2025 increased 37% to $94.7 million, compared to $69.0 million in the same period in 2024. Non-GAAP SG&A expenses for the fourth quarter of 2025 increased 38% to $94.5 million, compared to $68.6 million in the same period in 2024.
GAAP and non-GAAP research and development (R&D) expenses for the fourth quarter of 2025 increased 20% to $43.7 million, compared to $36.5 million in the same period in 2024.
Loss from operations in the fourth quarter of 2025 was $139.9 million, compared to operating loss of $28.7 million in the fourth quarter of 2024. Non-GAAP loss from operations in the fourth quarter of 2025 was $16.4 million, compared to non-GAAP operating loss of $18.3 million in the fourth quarter of 2024.
1
Net loss in the fourth quarter of 2025 was $133.7 million, or ($2.32) per diluted share, compared to net loss of $33.6 million, or ($0.60) per diluted share, in the fourth quarter of 2024. Non-GAAP net loss in the fourth quarter of 2025 was $16.4 million, or ($0.28) per diluted share, compared to non-GAAP net loss of $22.2 million, or ($0.40) per diluted share, in the fourth quarter of 2024.
Included in GAAP gross margin, GAAP loss from operations, GAAP net loss, and GAAP EPS for the fourth quarter of 2025 is a one-time, non-cash impairment charge of $112.9 million related to an acquired intangible asset associated with the Avedro acquisition, reflecting the Photrexa® to Epioxa™ transition.
Full Year 2025 Financial Results
Net sales in 2025 of $507.4 million increased 32%, both on a reported and constant currency basis, compared to $383.5 million in 2024.
Gross margin for 2025 was approximately 56%, compared to approximately 75% in 2024. Non-GAAP gross margin for 2025 was approximately 84%, compared to approximately 82% in 2024.
SG&A expenses in 2025 increased 27% to $331.7 million, compared to $261.2 million in 2024. Non-GAAP SG&A expenses in 2025 increased 28% to $331.5 million, compared to $258.6 million in 2024.
GAAP and non-GAAP R&D expenses in 2025 increased 10% to $150.6 million, compared to $136.4 million in 2024.
Loss from operations in 2025 was $199.6 million, compared to operating loss of $122.4 million in 2024. Non-GAAP loss from operations in 2025 was $57.4 million, compared to non-GAAP operating loss of $93.3 million in 2024.
Net loss in 2025 was $187.7 million, or ($3.28) per diluted share, compared to net loss of $146.4 million, or ($2.77) per diluted share, in 2024. Non-GAAP net loss in 2025 was $51.7 million, or ($0.90) per diluted share, compared to non-GAAP net loss of $98.3 million, or ($1.86) per diluted share, in 2024.
Included in GAAP gross margin, GAAP loss from operations, GAAP net loss, and GAAP EPS for 2025 is a one-time, non-cash impairment charge of $112.9 million related to an acquired intangible asset associated with the Avedro acquisition, reflecting the Photrexa to Epioxa transition.
The company ended the fourth quarter of 2025 with approximately $282.6 million in cash and cash equivalents, short-term investments and restricted cash, and no debt.
2026 Revenue Guidance
The company expects 2026 net sales to be in the range of $600 million to $620 million based on the latest foreign currency exchange rates.
Webcast & Conference Call
The company will host a conference call and simultaneous webcast today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results and provide additional information about the company’s financial outlook. A link to the webcast is available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.) or 646-307-1963 (international) and enter Conference ID 5255602. A replay of the webcast will be archived on the company’s website following completion of the call.
2
Quarterly Summary Document
The company has posted a document on its Investor Relations website under the “Financials & Filings – Quarterly Results” section titled “Quarterly Summary.” This Quarterly Summary document is designed to provide the investment community with a summarized and easily accessible reference document that details the key facts associated with the quarter, the state of the company’s business objectives and strategies, and any forward statements or guidance the company may make. This document is provided alongside the company’s earnings press release and is designed to be read by investors before the regularly scheduled quarterly conference call. It is the company’s goal that this format will make its quarterly earnings process more efficient and impactful for the investment community.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of federal securities laws. All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, our ability to successfully commercialize our iDose TR or Epioxa therapies; the impact of general macroeconomic conditions including foreign currency fluctuations and future health crises on our business; our ability to continue to generate sales of our commercialized products and develop and commercialize additional products; our dependence on a limited number of third-party suppliers, some of which are single-source, for components of our products; the occurrence of a crippling accident, natural disaster, or other disruption at our primary facility, which may materially affect our manufacturing capacity and operations; securing or maintaining adequate coverage or reimbursement by governmental or third-party payors for procedures using our existing products or other products in development, and our compliance with the requirements of participation in federal healthcare programs such as Medicare and Medicaid; our compliance with federal, state and foreign laws and regulations for the approval and sale and marketing of our products and of our manufacturing processes; the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes; the risk of recalls or serious safety issues with our products and the uncertainty of patient outcomes; our ability to protect our
3
information systems against cyber threats and cybersecurity incidents, and to comply with state, federal and foreign data privacy laws and regulations; our ability to protect, and the expense and time-consuming nature of protecting our intellectual property against third parties and competitors and the impact of any claims against us for infringement or misappropriation of third party intellectual property rights and any related litigation; and our ability to service our indebtedness. These and other known risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission (SEC), including in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, which was filed with the SEC on October 31, 2025, and our Annual Report on Form 10-K for the year ended December 31, 2025, which is expected to be filed with the SEC by March 2, 2026. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
Statement Regarding Use of Non-GAAP Financial Measures
To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses certain non-GAAP historical financial measures. Management makes adjustments to the GAAP measures for items (both charges and gains) that (a) do not reflect the core operational activities of the Company, (b) are commonly adjusted within the Company's industry to enhance comparability of the Company's financial results with those of its peer group, or (c) are inconsistent in amount or frequency between periods (albeit such items are monitored and controlled with equal diligence relative to core operations) (“Non-GAAP Purposes”). The Company uses the term "Non-GAAP" to exclude certain expenses, gains and losses to achieve the Non-GAAP Purposes, including external acquisition-related costs incurred to effect a business combination; amortization of intangible assets acquired in a business combination, asset purchase transaction or other contractual relationship; impairment of goodwill and intangible assets; certain in-process R&D charges; fair value adjustments to contingent consideration liabilities and pre-acquisition contingencies arising from a business combination; integration and transition costs related to business combinations; fair market value adjustments to inventories acquired in a business combination or asset purchase transaction; restructuring charges, duplicative operating expenses, or asset write-offs (or reversals) associated with exiting or significantly downsizing a business; unusual non-recurring expenses associated with inventory write-downs; gain or loss from the sale of a business; gain or loss on the mark-to-market adjustment, impairment, or sale of long-term investments; mark-to-market adjustments on derivative instruments that hedge income or expense exposures in a future period; significant legal litigation costs and/or settlement expenses or proceeds; legal and other associated expenses that are both unusual and significant related to governmental or internal inquiries; expenses, acceleration of amortization of debt issuance costs and gain or loss on debt extinguishment associated with the exchange or redemption of convertible senior notes; significant discrete income and other tax adjustments related to transactions as well as changes in estimated acquisition-date tax effects associated with business combinations, and the impact from implementation of tax law changes and settlements; and any other adjustment that is determined to be appropriate and consistent with the Non-GAAP Purposes. See “GAAP to Non-GAAP Reconciliations” for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure.
In addition, in order to remove the impact of fluctuations in foreign currency exchange rates, the Company also presents certain net sales information on a constant currency basis, which represents the outcome that would have resulted had exchange rates in the current period been the same as the average exchange rates in effect in the comparable prior period. See “Reported Sales vs. Prior Periods” for a presentation of certain net sales information on a reported, GAAP and a constant currency basis.
4
GLAUKOS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share amounts)
| | Three Months Ended | | Year Ended | ||||||||
| | December 31, | | December 31, | ||||||||
| | 2025 | | 2024 | | 2025 | | 2024 | ||||
Net sales | | $ | 143,121 | | $ | 105,499 | | $ | 507,442 | | $ | 383,481 |
Cost of sales | | | 31,771 | | | 28,635 | | | 111,814 | | | 94,027 |
Impairment of intangible asset | | | 112,867 | | | — | | | 112,867 | | | — |
Gross profit | | | (1,517) | | | 76,864 | | | 282,761 | | | 289,454 |
Operating expenses: | | | | | | | | | | | | |
Selling, general and administrative | | | 94,700 | | | 69,003 | | | 331,747 | | | 261,166 |
Research and development | | | 43,651 | | | 36,527 | | | 150,614 | | | 136,425 |
Acquired in-process research and development | | | — | | | — | | | — | | | 14,229 |
Total operating expenses | | | 138,351 | | | 105,530 | | | 482,361 | | | 411,820 |
Loss from operations | | | (139,868) | | | (28,666) | | | (199,600) | | | (122,366) |
Non-operating income (expense): | | | | | | | | | | | | |
Interest income | | | 2,512 | | | 2,494 | | | 10,714 | | | 11,105 |
Interest expense | | | (1,146) | | | (1,572) | | | (4,635) | | | (10,040) |
Charges associated with convertible senior notes | | | — | | | — | | | — | | | (18,012) |
Other (expense) income, net | | | (1,314) | | | (5,950) | | | 479 | | | (6,288) |
Total non-operating income (expense) | | | 52 | | | (5,028) | | | 6,558 | | | (23,235) |
Loss before taxes | | | (139,816) | | | (33,694) | | | (193,042) | | | (145,601) |
Income tax (benefit) provision | | | (6,159) | | | (114) | | | (5,351) | | | 771 |
Net loss | | $ | (133,657) | | $ | (33,580) | | $ | (187,691) | | $ | (146,372) |
| | | | | | | | | | | | |
Basic and diluted net loss per share | | $ | (2.32) | | $ | (0.60) | | $ | (3.28) | | $ | (2.77) |
| | | | | | | | | | | | |
Weighted-average shares outstanding used to compute basic and diluted net loss per share | | | 57,506 | | | 55,584 | | | 57,190 | | | 52,755 |
5
GLAUKOS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except par values)
| | December 31, | | December 31, | ||
| | 2025 | | 2024 | ||
| | (unaudited) | | | ||
Assets | | | | | ||
Current assets: | | | | | ||
Cash and cash equivalents | | $ | 90,813 | | $ | 169,626 |
Short-term investments | | | 187,947 | | | 149,289 |
Accounts receivable, net | | | 108,608 | | | 60,744 |
Inventory | | | 63,564 | | | 57,678 |
Prepaid expenses and other current assets | | | 24,052 | | | 12,455 |
Total current assets | | | 474,984 | | | 449,792 |
Restricted cash | | | 3,834 | | | 4,733 |
Property and equipment, net | | | 113,253 | | | 97,867 |
Operating lease right-of-use asset | | | 31,527 | | | 30,254 |
Finance lease right-of-use asset | | | 39,404 | | | 41,816 |
Intangible assets, net | | | 141,916 | | | 263,445 |
Goodwill | | | 66,710 | | | 66,134 |
Deposits and other assets | | | 21,859 | | | 20,715 |
Total assets | | $ | 893,487 | | $ | 974,756 |
| | | | | | |
Liabilities and stockholders' equity | | | | | | |
Current liabilities: | | | | | | |
Accounts payable | | $ | 24,624 | | $ | 13,026 |
Accrued liabilities | | | 76,651 | | | 62,099 |
Total current liabilities | | | 101,275 | | | 75,125 |
Operating lease liability | | | 35,767 | | | 33,936 |
Finance lease liability | | | 68,109 | | | 69,463 |
Deferred tax liability, net | | | 441 | | | 6,928 |
Other liabilities | | | 31,740 | | | 22,373 |
Total liabilities | | | 237,332 | | | 207,825 |
| | | | | | |
Stockholders' equity: | | | | | | |
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares | | | | | | |
issued and outstanding as of December, 2025 and December 31, 2024 | | | — | | | — |
Common stock, $0.001 par value; 150,000 shares authorized; 57,539 | | | | | | |
and 56,472 shares issued and 57,511 and 56,544 shares outstanding | | | | | | |
at December 31, 2025 and December 31, 2024, respectively | | | 58 | | | 56 |
Additional paid-in capital | | | 1,586,056 | | | 1,509,831 |
Accumulated other comprehensive income | | | 3,303 | | | 2,615 |
Accumulated deficit | | | (933,130) | | | (745,439) |
Less treasury stock (28 shares as of December 31, 2025 and December 31, 2024) | | | (132) | | | (132) |
Total stockholders' equity | | | 656,155 | | | 766,931 |
Total liabilities and stockholders' equity | | $ | 893,487 | | $ | 974,756 |
6
GLAUKOS CORPORATION
GAAP to Non-GAAP Reconciliations
(in thousands, except per share amounts and percentage data)
(unaudited)
| | Q4 2025 | | Q4 2024 | | ||||||||||||||
| | GAAP | | Adjustments | | Non-GAAP | | GAAP | | Adjustments | | Non-GAAP | | ||||||
Cost of sales | | $ | 31,771 | | $ | (10,452) | (a)(b)(c) | $ | 21,319 | | $ | 28,635 | | $ | (9,972) | (a)(c) | $ | 18,663 | |
| | | | | | | | | | | | | | | | | | | |
Impairment of intangible asset | | $ | 112,867 | | $ | (112,867) | (d) | $ | — | | $ | — | | $ | — | | $ | — | |
| | | | | | | | | | | | | | | | | | | |
Gross Margin | | | (1.1) | % | | 86.2 | % | | 85.1 | % | | 72.9 | % | | 9.4 | % | | 82.3 | % |
| | | | | | | | | | | | | | | | | | | |
Operating expenses: | | | | | | | | | | | | | | | | | | | |
Selling, general and administrative | | $ | 94,700 | | $ | (187) | (e) | $ | 94,513 | | $ | 69,003 | | $ | (411) | (f) | $ | 68,592 |
|
Loss from operations | | $ | (139,868) | | $ | 123,506 | | $ | (16,362) | | $ | (28,666) | | $ | 10,383 | | $ | (18,283) | |
| | | | | | | | | | | | | | | | | | | |
Non-operating (expense) income: | | | | | | | | | | | | | | | | | | | |
Other (expense) income, net | | $ | (1,314) | | $ | — | | $ | (1,314) | | $ | (5,950) | | $ | 951 | (g) | $ | (4,999) | |
| | | | | | | | | | | | | | | | | | | |
Income tax (benefit) provision | | $ | (6,159) | | $ | 6,204 | (h) | $ | 45 | | | (114) | | $ | — | | $ | (114) | |
| | | | | | | | | | | | | | | | | | | |
Net loss | | $ | (133,657) | | $ | 117,302 | (i) | $ | (16,355) | | $ | (33,580) | | $ | 11,334 | (i) | $ | (22,246) | |
Basic and diluted net loss per share | | $ | (2.32) | | $ | 2.04 | | $ | (0.28) | | $ | (0.60) | | $ | 0.20 | | $ | (0.40) | |
(a) | Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $8.6 million in Q4 2025 and $5.5 million in Q4 2024. |
(b) | Mobius acquisition-related amortization expense of developed intellectual property of $0.5 million. |
(c) | Inventory write-down charges associated with the transition from Photrexa to Epioxa of $1.3 million in Q4 2025 and product line optimizations of $4.4 million in Q4 2024. |
(d) | Impairment of intangible asset associated with the transition from Photrexa to Epioxa. |
(e) | Mobius contingent consideration fair value adjustment. |
(f) | Avedro acquisition-related amortization expense of customer relationship intangible assets of $0.4 million. |
(g) | Remeasurement loss on derivative asset and direct transaction costs associated with the capped call unwind agreements. |
(h) | Tax effect from conversion of Avedro acquisition developed technology intangible asset from indefinite-lived to finite-lived. |
(i) | Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2025 and 2024. |
7
GLAUKOS CORPORATION
GAAP to Non-GAAP Reconciliations
(in thousands, except per share amounts and percentage data)
(unaudited)
| | Full Year 2025 | | Full Year 2024 | | ||||||||||||||
| | GAAP | | Adjustments | | Non-GAAP | | GAAP | | Adjustments | | Non-GAAP | | ||||||
Cost of sales | | $ | 111,814 | | $ | (29,049) | (a)(b)(c)(d) | $ | 82,765 | | $ | 94,027 | | $ | (26,541) | (a)(d) | $ | 67,486 | |
| | | | | | | | | | | | | | | | | | | |
Impairment of intangible asset | | $ | 112,867 | | $ | (112,867) | (e) | $ | — | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | |
Gross Margin | | | 55.7 | % | | 28.0 | % | | 83.7 | % | | 75.5 | % | | 6.9 | % | | 82.4 | % |
| | | | | | | | | | | | | | | | | | | |
Operating expenses: | | | | | | | | | | | | | | | | | | | |
Selling, general and administrative | | $ | 331,747 | | $ | (239) | (f) | $ | 331,508 | | $ | 261,166 | | $ | (2,526) | (g) | $ | 258,640 |
|
Loss from operations | | $ | (199,600) | | $ | 142,155 | | $ | (57,445) | | $ | (122,366) | | $ | 29,067 | | $ | (93,299) | |
| | | | | | | | | | | | | | | | | | | |
Non-operating expense: | | | | | | | | | | | | | | | | | | | |
Charges associated with convertible senior notes | | $ | — | | $ | — | | $ | — | | $ | (18,012) | | $ | 18,012 | (h) | $ | — | |
Other income (expense), net | | $ | 479 | | $ | — | | $ | 479 | | $ | (6,288) | | $ | 951 | (i) | $ | (5,337) | |
Income tax (benefit) provision | | $ | (5,351) | | $ | 6,204 | (j) | $ | 853 | | $ | 771 | | $ | — | | $ | 771 | |
Net loss | | $ | (187,691) | | $ | 135,951 | (k) | $ | (51,740) | | $ | (146,372) | | $ | 48,030 | (k) | $ | (98,342) | |
Basic and diluted net loss per share | | $ | (3.28) | | $ | 2.38 | | $ | (0.90) | | $ | (2.77) | | $ | 0.91 | | $ | (1.86) | |
(a) | Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $25.2 million in 2025 and $22.1 million in 2024. |
(b) | Mobius acquisition-related amortization expense of developed intellectual property of $1.2 million. |
(c) | Non-recurring, non-cash charge related to the write-down of certain inventory of $1.3 million. |
(d) | Inventory write-down charges associated with the transition from Photrexa to Epioxa of $1.3 million in 2025 and product line optimizations of $4.4 million in 2024. |
(e) | Impairment of intangible asset associated with the transition from Photrexa to Epioxa. |
(f) | Mobius acquisition-related transaction expense of $0.3 million and contingent consideration fair value adjustment of ($0.1) million. |
(g) | Avedro acquisition-related amortization expense of customer relationship intangible assets. |
(h) | Expenses associated with the exchange of convertible senior notes, consisting of a non-cash inducement charge of $17.4 million and direct transaction costs of $0.6 million. |
(i) | Remeasurement loss on derivative asset and direct transaction costs associated with the capped call unwind agreements |
(j) | Tax effect from conversion of Avedro acquisition developed technology intangible asset from indefinite-lived to finite-lived. |
(k) | Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2025 and 2024. |
8
Reported Sales vs. Prior Periods (in thousands) | |||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | Year-over-Year Percent Change | | | Quarter-over-Quarter Percent Change | |||||||||||||||||||||||||||||||
| | 4Q 2025 | | 4Q 2024 | | 3Q 2025 | | | Reported | | Operations (1) | | Currency (2) | | | Reported | | Operations (1) | | Currency (2) | |||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | |||||||||||||||||||||||
International Glaucoma | | $ | 32,779 | | $ | 27,869 | | $ | 29,443 | | | 17.6 | % | 13.1 | % | 4.5 | % | | 11.3 | % | 12.7 | % | (1.4%) | ||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||
Total Net Sales | | $ | 143,121 | | $ | 105,499 | | $ | 133,537 | | | 35.7 | % | 34.5 | % | 1.2 | % | | 7.2 | % | 7.5 | % | (0.3%) | ||||||||||||||||||||
(1) Operational growth excludes the effect of translational currency
(2) Calculated by converting the current period numbers using the prior period’s average foreign exchange rates
Reported Sales vs. Prior Periods (in thousands) | |||||||||||||
| | | | | | Year-over-Year Percent Change | | ||||||
| | 2025 | | 2024 | | Reported | | Operations (1) | | Currency (2) | | ||
| | | | | | | | | | | | ||
International Glaucoma | | $ | 122,482 | | $ | 103,705 | | 18.1 | % | 16.0 | % | 2.1 | % |
| | | | | | | | | | | | | |
Total Net Sales | | $ | 507,442 | | $ | 383,481 | | 32.3 | % | 31.7 | % | 0.6 | % |
(1) Operational growth excludes the effect of translational currency
(2) Calculated by converting the current period numbers using the prior period’s average foreign exchange rates
9
Exhibit 99.2
| FEBRUARY 17, 2026 |
GLAUKOS CORPORATION (NYSE: GKOS)
FOURTH QUARTER AND FULL YEAR 2025 IN REVIEW
Important Information
This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation’s recent financial and operational performance and general business outlook.
Please see “Forward-Looking Statements” and “Statement Regarding Use of Non-GAAP Financial Measures” in the “Additional Information” section of this document.
Conference Call Information
Date: | February 17, 2026 |
| |
Time: | 4:30 p.m. ET / 1:30 p.m. PT |
| |
Dial-in numbers: | 1-800-715-9871 (U.S.), 1-646-307-1963 (International) |
| |
Confirmation ID: | 5255602 |
| |
Live webcast: | Events page at the Glaukos Investor Relations website at http://investors.glaukos.com or at this link. |
| |
Webcast replay: | A replay of the webcast will be archived on the Glaukos Investor Relations website following completion of the call. |
1
| FEBRUARY 17, 2026 |
FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS SUMMARY
Business Description | Ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel, dropless platform therapies designed to disrupt the conventional standard of care and improve outcomes for patients suffering from chronic eye diseases | |
Disease Categories | Glaucoma Corneal Health Retinal Disease | |
Revenue (Growth) | 4Q 2025 $143.1 million (+36% reported and +34% constant currency versus 4Q 2024) | FY 2025 $507.4 million (+32% reported and constant currency versus FY 2024) |
Gross Margin (Non-GAAP) | 4Q 2025 ~85% (versus ~82% in 4Q 2024) | FY 2025 ~84% (versus ~82% in FY 2024) |
Cash & Cash Equivalents, Short-Term Investments, and Restricted Cash | $282.6 million as of December 31, 2025 (versus $277.5 million as of September 30, 2025) | |
FY2026 Sales Guidance | FY 2026 global consolidated revenues of $600 - $620 million expected | |
See “Statement Regarding Use of Non-GAAP Financial Measures” and the Non-GAAP reconciliations included within the Additional Information section of this document. Reconciliations for each of constant currency revenue growth, Non-GAAP Gross Margin, and the other non-GAAP financial measures disclosed in this document to the most directly comparable GAAP financial measure are provided.
2
| FEBRUARY 17, 2026 |
Revenue Performance & Commercial Overview
Global Consolidated Revenue Performance
Glaukos reported record fourth quarter net revenues of $143.1 million that were up 36% on a reported basis, or 34% on a constant currency basis, versus 4Q 2024. Our fourth quarter record results reflect a sustained growth acceleration in our business with the strong performance driven by growing iDose® TR adoption and utilization, along with our broader Interventional Glaucoma, or IG, initiatives globally.
For fiscal year 2025, net revenues were approximately $507 million, up 32% compared to net revenues of approximately $383 million in 2024.
3
| FEBRUARY 17, 2026 |
Franchise Revenue Performance
U.S. Glaucoma
Our record fourth quarter U.S. Glaucoma net revenues were approximately $86.4 million, representing year-over-year growth of 53% versus 4Q 2024 driven by growing contributions from iDose TR, which generated sales of approximately $45 million in the third quarter.
For fiscal year 2025, U.S. Glaucoma net revenues were approximately $298.6 million, representing year-over-year growth of 50% versus fiscal year 2024, including iDose TR sales of approximately $136 million.
During the fourth quarter, we successfully advanced execution of our detailed launch plans for iDose TR, a first-of-its-kind intracameral procedural pharmaceutical that was designed to continuously deliver glaucoma drug therapy for up to three years. Most importantly, clinical outcomes and product feedback from a growing number of cases and trained surgeons continue to be very positive and reaffirm our view that with the launch of iDose TR, we have the potential to reshape glaucoma management as we know it today.
International Glaucoma
Our record fourth quarter International Glaucoma net revenues were approximately $32.8 million, representing year-over-year growth of 18% on a reported basis, or 13% on a constant currency basis, versus 4Q 2024. The strong growth internationally during the fourth quarter was broad-based as we continue to scale our international infrastructure and increasingly drive MIGS forward as the standard of care in each region and major market in the world.
For fiscal year 2025, International Glaucoma net revenues were approximately $122.5 million, representing year-over-year reported growth of 18%, or 16% on a constant currency basis, versus fiscal year 2024.
We remain in the early stages of expanding our IG and product portfolio initiatives globally ahead of anticipated new product approvals and expanding market access in the years to come.
Corneal Health
Our record fourth quarter Corneal Health net revenues were approximately $24.0 million, representing year-over-year growth of 12% versus 4Q 2024, including U.S. Photrexa® net sales of $21.4 million. As
4
| FEBRUARY 17, 2026 |
discussed previously, these fourth quarter results reflect the continued impact to Photrexa realized revenues as a result of our entry as a company into the Medicaid Drug Rebate Program (MDRP).
For fiscal year 2025, Corneal Health net revenues were approximately $86.4 million, representing year-over-year reported growth of 8% versus fiscal year 2024. U.S Photrexa sales in 2025 were $75.0 million, an increase of 9% compared to 2024.
We will continue to focus on expanding access for keratoconus patients suffering from this rarely diagnosed disease.
5
| FEBRUARY 17, 2026 |
Additional Commercial Updates & Commentary
We have had several additional positive commercial updates worth highlighting here:
✓ | Advanced commercial launch activities in the U.S. for iDose TR |
| o | Growing number of trained surgeons and accounts |
| o | Expanding utilization of the installed active surgeon base |
| o | Broadening and streamlining market access among MACs, commercial, and Medicare Advantage payers |
| o | Expanded set of peer-reviewed literature, now consisting of 17 different peer-reviewed publications highlighting iDose TR as a transformative new treatment alternative for patients suffering with glaucoma and ocular hypertension |
| o | Accelerating marketing investments to support increased patient awareness and education |
✓ | Commenced initial commercial launch plans for Epioxa™ following October 2025 FDA approval |
| o | Establishing site-of-care network with acquired O2N systems already actively deployed at locations covering nearly 50% of the U.S. population, and a broader pipeline of systems moving through approval processes that would expand our treatment reach closer to 90% |
| o | Market access: |
| ● | Completed initial payer communications and updated key payer databases with details associated with Epioxa launch |
| ● | Actively engaging with insurers representing approximately 50% of commercially covered lives in the U.S., including 4 of the top 5 commercial insurers |
| ● | Successfully submitted for permanent J-Code; anticipate July 2026 effective date |
| o | Deployed various new patient services and support programs |
| o | Developing new marketing and DTC campaigns designed to significantly enhance awareness, education, and detection |
| o | Introduced new financial co-pay assistance program and operationalized Specialty Pharmacy option available for our customers at launch |
| o | Epioxa drug availability expected in late Q1 2026 |
6
| FEBRUARY 17, 2026 |
2026 Revenue Guidance Reaffirmed
Glaukos expects full-year 2026 global consolidated net sales of $600 - $620 million. This guidance attempts to take into consideration:
| ● | Potential growing contributions from iDose TR as reimbursement confidence grows and broader IG initiatives take hold over the course of the year |
| ● | Potential growing contributions from iStent infinite as broader IG initiatives take hold |
| ● | Potential growing contributions from Epioxa as commercial launch plans advance |
| ● | Potential transient headwinds within our U.S. Corneal Health franchise associated with the Photrexa to Epioxa transition |
| ● | Combo-cataract MIGS competition globally |
| ● | The continued estimated impact on U.S. Glaucoma volumes related to professional fee reimbursement for combination-cataract trabecular bypass surgery versus other more invasive alternatives |
| ● | The latest foreign currency exchange spot rates as of our 4Q 2025 earnings call on February 17, 2026 |
| ● | Global macroeconomic environment and associated uncertainties, which at this time are difficult to predict |
7
| FEBRUARY 17, 2026 |
Research & Development / Pipeline Overview
Pipeline Summary
Our five key dropless technology therapy platforms designed to disrupt traditional treatment paradigms and generate cascades of future innovation are as follows:
· | iStent® micro-scale surgical devices |
· | iDose® sustained-release procedural pharmaceuticals |
· | iLink® bio-activated pharmaceuticals |
· | iLution™ transdermal pharmaceuticals |
· | Retina XR bio-erodible sustained-release pharmaceuticals |
8
| FEBRUARY 17, 2026 |
Key R&D and Pipeline Updates
We are continuing to invest in and advance our fulsome pipeline of core novel platforms, supported by more than $800 million investment into R&D since 2018 alone. Recent updates in our pipeline include:
| iDose Platform Updates |
✓ | Announced U.S. FDA approval for NDA labeling supplement allowing for unlimited re-administration of iDose TR in patients who maintain a healthy cornea (January 2026) |
✓ | Advancing patient enrollment in Phase 2b/3 clinical program for iDose TREX, our next-generation iDose therapy |
o | Initial results of Phase 2a clinical trial demonstrated substantial IOP reductions of 8.6 to 10.8 mmHg through 3 months |
✓ | Commenced Phase 3b study for iDose TRIO |
o | Initial human factors study indicated strong user preference (~90% favorability) |
✓ | Advancing various Phase 4 studies for iDose TR |
| iLink Platform Updates |
✓ | Announced U.S. FDA approval for Epioxa (Epi-on) (October 2025) |
| o | Epioxa is a groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening disease that is currently far too often undiagnosed and untreated |
| o | Epioxa ushers in a new standard of care for patients |
| o | Epioxa expected to be commercially available in Q1 2026 |
✓ | Advancing development of KC screening tool to support planned commercialization in 2H 2026 |
✓ | Preparing to commence Phase 3 clinical program for third-generation iLink therapy in 2027 |
✓ | Commenced Phase 2 clincial trial for iVeena (4Q 2025) |
9
| FEBRUARY 17, 2026 |
| iStent Platform Updates |
✓ | Completed patient enrollment in PMA pivotal trial for iStent infinite in mild-to-moderate glaucoma patients (4Q 2025) |
✓ | Announced EU MDR certification for iStent infinite (June 2025) |
✓ | Advancing 510(k) pivotal study for PRESERFLO™ MicroShunt |
| iLution Platform Updates |
✓ | Commenced Phase 2 clinical trial for iLution™ Blepharitis (4Q 2025) |
| Retina XR Platform Updates |
✓ | Completed patient enrollment in first-in-human Retina XR clinical development program for IVT multi-kinase inhibitor in wet AMD patients (GLK-401) (4Q 2025) |
10
| FEBRUARY 17, 2026 |
Product / Pipeline Chart
11
| FEBRUARY 17, 2026 |
Other Financial Performance Overview
As a reminder, we discuss our financial performance on a non-GAAP basis and summarize our GAAP performance. We encourage investors to review our GAAP to non-GAAP reconciliation which can be found in our earnings press release, the Additional Information section contained herein, as well as the Investor Relations section of our website.
Fourth quarter 2025 financial performance summary:
 Gross Margin (Non-GAAP) | 4Q 2025: 85% 4Q 2024: 82% YoY ∆: +280 bps | ● Please note that our non-GAAP adjustments to cost of goods sold include substantial amounts related to Avedro and Mobius acquisitions accounting |
SG&A (Non-GAAP) | 4Q 2025: $94.5M 4Q 2024: $68.6M YoY ∆: +38% | ● +14% sequentially vs $83.2M in 3Q 2025 ● YoY and QoQ increases primarily reflect commercial and G&A investments globally and new product launch activities, along with $4.7M in one-time stock compensation expenses associated with the triggering of certain performance awards in 4Q 2025 |
R&D (Non-GAAP) | 4Q 2025: $43.7M 4Q 2024: $36.5M YoY ∆: +20% | ● +15% sequential increase vs $38.1M in 3Q 2025 ● YoY and QoQ increases reflect continued investment in and advancement of R&D programs |
SG&A + R&D (Non-GAAP) | 4Q 2025: $138.2M 4Q 2024: $105.1M YoY ∆: +31% | ● +14% sequential increase vs $121.3M in 3Q 2025 |
Earnings | Op Loss (Non-GAAP) 4Q 2025 ($16.4M) 4Q 2024: ($18.3M) Net Loss (Non-GAAP) 4Q 2025: ($16.4M) 4Q 2024: ($22.2M) Diluted EPS (Non-GAAP) 4Q 2025: ($0.28) 4Q 2024: ($0.40) | |
 CapEx | 4Q 2025: $2.9M 4Q 2024: $1.7M YoY ∆: +$1.2M | ● Capital expenditures have moderated to levels more consistent with historical norms |
 Cash | 4Q 2025: $282.6M 3Q 2025: $277.5M QoQ ∆: +$5.1M | |
12
| FEBRUARY 17, 2026 |
Other Important Updates
Ø | During the third quarter of 2025, we celebrated the groundbreaking of our new state-of-the-art research, development, and manufacturing facility in Huntsville, Alabama. We are proud to expand our U.S. footprint with the development of this new state-of-the-art facility to augment our current infrastructure and support our long-term growth plans. The new site represents a major milestone in the company’s commitment to strengthening U.S. manufacturing, creating high-quality jobs, and driving the next generation of innovation in American healthcare. |
Ø | Given the ongoing conversations around tariff and geopolitical issues, we wanted to highlight that we manufacture and source our products primarily within the U.S., and as such, expect minimal direct exposure to the most recently implemented tariff-related policies. That said, the tariff dynamics obviously remain highly fluid. As such, we will continue to closely monitor the situation given the overall instability in the marketplace and global macroeconomic uncertainties. |
13
| FEBRUARY 17, 2026 |
14
| FEBRUARY 17, 2026 |
Delivering the Portfolio for Sustainable Long-Term Growth & Value Creation
While we execute commercially, we continue to successfully invest in and advance our robust pipeline of novel, promising platform technologies that we believe can significantly expand our addressable markets and leverage our commercial platform to fundamentally transform our company over time.
We believe the strong financial profile and capital position we’ve built provides a solid foundation that allows us to remain on offense when it comes to successfully investing for our future, leaving us well-positioned for the next phase of our pioneering journey as we target clinical, regulatory, and commercial milestones in the years ahead.
Our mission is to disrupt conventional treatment paradigms to advance the existing standard of care and enrich the lives and treatment alternatives for patients worldwide suffering from sight-threatening chronic eye diseases. We believe our platforms and product candidates have the ability to generate a robust cadence of new product introductions over the coming years that can generate layers of future growth.
2025 was an important year for Glaukos as we successfully executed on our core business key strategic objectives while achieving notable pipeline advancements and milestones that leave us excited about our prospects and well-positioned for the next phase of our pioneering journey.
15
| FEBRUARY 17, 2026 |
Key Technology Platforms
Our platforms embody ambitious, big ideas aimed at addressing large and chronically underserved eye diseases, including for glaucoma, corneal disorders, and retinal diseases. Over the years the number of disclosed pipeline programs associated with these platforms has expanded significantly to 13 entering into 2026.
iStent Micro-Scale Surgical Devices
Our foundational iStent micro-surgical device platform primarily involves the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma. We believe our iStent portfolio is the industry’s most comprehensive offering of minimally-invasive, tissue-sparing glaucoma solutions, supporting our goal to provide a full range of options to fit surgeons’ individual glaucoma treatment algorithms that offer the best short- and long-term benefit-to-risk calculus at every stage of disease progression, from ocular hypertension through refractory disease, and in both combo-cataract and standalone procedures. We are proud to be the corporate pioneer and global market leader in MIGS, with our family of iStent technologies supported by more than 400 peer-reviewed publications, 20+ years of clinical and commercial experience, and 1+ million iStent devices implanted worldwide since our inception.
iDose Sustained-Release Procedural Pharmaceuticals
Our iDose sustained-release procedural pharmaceutical platform consists of a targeted, minimally-invasive, injectable implant designed to deliver therapeutic levels of medication from within the eye for extended periods of time. Designed to address ubiquitous patient non-adherence and chronic side effects associated with topical medications by providing continuous, long-duration, robust efficacy with minimal side effects. Given our development success to date with iDose TR, we continue to invest resources to expand our pharmaceutical development capabilities and develop future iDose solutions.
16
| FEBRUARY 17, 2026 |
iLink Bio-Activated Pharmaceuticals
Our iLink bio-activated pharmaceutical platform consists of novel single-use drug formulations that are bio-activated by our proprietary systems through the delivery of ultraviolet light to the cornea to induce a biochemical reaction called corneal cross-linking designed to strengthen, stabilize, and reshape the cornea. Even though keratoconus is a serious sight-threatening disease and the leading cause of full thickness corneal transplants in the U.S., we believe it remains vastly undertreated. This undertreatment is due primarily to under-diagnosis and the historical lack of an effective solution. With the launch of Epioxa, we plan to make substantial investments in patient awareness and access while addressing the longstanding challenges of underdiagnosis and undertreatment that have affected this rare disease patient community.
iLution Transdermal Pharmaceuticals
Our iLution transdermal pharmaceutical platform, which consists of patented cream-based drug formulations, are designed to be applied to the outer surface of the eyelid for dropless transdermal delivery of pharmaceutically active compounds for the treatment of eye disorders. We believe iLution’s differentiated delivery approach on the eyelid may offer significant advantages over traditional topical delivery, including the potential for easier administration, faster onset of action, and fewer side effects, such as reduced preservative induced corneal and conjunctival sequalae, all of which can help contribute to better compliance and improved patient outcomes.
Retina XR Bio-Erodible Sustained-Release Pharmaceuticals
Our bio-erodible sustained release pharmaceutical platform, known as Retina XR, is designed to treat retinal diseases, the largest market in ophthalmology today. The goal of these investigational programs is to provide retinal specialists and their patients with novel sustained pharmaceutical treatment options that offer meaningfully longer duration-of-effect than the current standard of care dominated by short-lasting biological injections that often impose tremendous treatment burdens on patients because of the high-frequency of required treatments.
17
| FEBRUARY 17, 2026 |
18
| FEBRUARY 17, 2026 |
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of federal securities laws. All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current expectations, assumptions, estimates and beliefs. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this presentation. These potential risks and uncertainties that could cause actual results to differ materially from those described in forward-looking statements include, without limitation, our ability to successfully commercialize our iDose TR or Epioxa therapies; the impact of general macroeconomic conditions including foreign currency fluctuations and future public health crises on our business; our ability to continue to generate sales of our commercialized products and develop and commercialize additional products; our dependence on a limited number of third-party suppliers, some of which are single-source, for components of our products; the occurrence of a crippling accident, natural disaster, or other disruption at our primary facility, which may materially affect our manufacturing capacity and operations; securing or maintaining adequate coverage or reimbursement by governmental or third-party payors for procedures using our existing products or other products in development, and our compliance with the requirements of participation in federal healthcare programs such as Medicare and Medicaid; our ability to properly train, and gain acceptance and trust from ophthalmic surgeons in the use of our products; our compliance with federal, state and foreign laws and regulations for the approval and sale and marketing of our products and of our manufacturing processes; the lengthy and expensive clinical trial process and the uncertainty of timing and outcomes from any particular clinical trial or regulatory approval processes; the risk of recalls or serious safety issues with our products and the uncertainty of patient outcomes; our ability to protect our information systems against cyber threats and cybersecurity incidents, and to comply with state, federal and foreign data privacy laws and regulations; our ability to protect, and the expense and time-consuming nature of protecting our intellectual property against third parties and competitors and the impact of any claims against us for infringement or misappropriation of third party intellectual property rights and any related litigation; and our ability to service our indebtedness. These and other known risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission (SEC), including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, which was filed with the SEC on October 31, 2025, and our Annual Report on Form 10-K for the year ended December 31, 2025, which we expect to file on or before March 2, 2026. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.
19
| FEBRUARY 17, 2026 |
Statement Regarding Use of Non-GAAP Financial Measures
To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses certain non-GAAP historical financial measures. Management makes adjustments to the GAAP measures for items (both charges and gains) that (a) do not reflect the core operational activities of the Company, (b) are commonly adjusted within the Company's industry to enhance comparability of the Company's financial results with those of its peer group, or (c) are inconsistent in amount or frequency between periods (albeit such items are monitored and controlled with equal diligence relative to core operations) (“Non-GAAP Purposes”). The Company uses the term "Non-GAAP" to exclude certain expenses, gains and losses to achieve the Non-GAAP purposes, including external acquisition-related costs incurred to effect a business combination; amortization of intangible assets acquired in a business combination, asset purchase transaction or other contractual relationship; impairment of goodwill and intangible assets; certain in-process R&D charges; fair value adjustments to contingent consideration liabilities and pre-acquisition contingencies arising from a business combination; integration and transition costs related to business combinations; fair market value adjustments to inventories acquired in a business combination or asset purchase transaction; restructuring charges, duplicative operating expenses, or asset write-offs (or reversals) associated with exiting or significantly downsizing a business; unusual non-recurring expenses associated with inventory write-downs; gain or loss from the sale of a business; gain or loss on the mark-to-market adjustment, impairment, or sale of long-term investments; mark-to-market adjustments on derivative instruments that hedge income or expense exposures in a future period; significant legal litigation costs and/or settlement expenses or proceeds; legal and other associated expenses that are both unusual and significant related to governmental or internal inquiries; expenses, acceleration of amortization of debt issuance costs and gain or loss on debt extinguishment with the exchange or redemption of convertible senior notes; and significant discrete income and other tax adjustments related to transactions as well as changes in estimated acquisition-date tax effects associated with business combinations, and the impact from implementation of tax law changes and settlements; and any other adjustment that is determined to be appropriate and consistent with the Non-GAAP Purposes. See “Primary GAAP to Non-GAAP Reconciliations” for a reconciliation of each non-GAAP measure presented to the comparable GAAP financial measure. Beginning in the second quarter of 2022, we no longer exclude certain upfront and contingent milestone payments in connection with collaborative and licensing arrangements and certain in-process R&D charges for non-GAAP reporting and disclosure purposes.
In addition, in order to remove the impact of fluctuations in foreign currency exchange rates, the Company also presents certain net sales information on a constant currency basis, which represents the outcome that would have resulted had exchange rates in the current period been the same as the average exchange rates in effect in the comparable prior period. See “Additional GAAP to Non-GAAP Reconciliations” for a presentation of certain net sales information on a reported, GAAP and a constant currency basis.
20
| FEBRUARY 17, 2026 |
GAAP Income Statement
GLAUKOS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share amounts)
| | Three Months Ended | | Year Ended | | ||||||||
| | December 31, | | December 31, | | ||||||||
| | 2025 | | | 2024 | | | 2025 | | | 2024 |
| |
Net sales | | $ | 143,121 | | $ | 105,499 | | $ | 507,442 | | $ | 383,481 | |
Cost of sales | | | 31,771 | | | 28,635 | | | 111,814 | | | 94,027 | |
Impairment of intangible asset | | | 112,867 | | | — | | | 112,867 | | | — | |
Gross profit | | | (1,517) | | | 76,864 | | | 282,761 | | | 289,454 | |
Operating expenses: | | | | | | | | | | ||||
Selling, general and administrative | | | 94,700 | | | 69,003 | | | 331,747 | | | 261,166 | |
Research and development | | | 43,651 | | | 36,527 | | | 150,614 | | | 136,425 | |
Acquired in-process research and development | | | — | | | — | | | — | | | 14,229 | |
Total operating expenses | | | 138,351 | | | 105,530 | | | 482,361 | | | 411,820 | |
Loss from operations | | | (139,868) | | | (28,666) | | | (199,600) | | | (122,366) | |
Non-operating income (expense): | | | | | | | | | | ||||
Interest income | | | 2,512 | | | 2,494 | | | 10,714 | | | 11,105 | |
Interest expense | | | (1,146) | | | (1,572) | | | (4,635) | | | (10,040) | |
Charges associated with convertible senior notes | | | — | | | — | | | — | | | (18,012) | |
Other (expense) income, net | | | (1,314) | | | (5,950) | | | 479 | | | (6,288) | |
Total non-operating income (expense) | | | 52 | | | (5,028) | | | 6,558 | | | (23,235) | |
Loss before taxes | | | (139,816) | | | (33,694) | | | (193,042) | | | (145,601) | |
Income tax (benefit) provision | | | (6,159) | | | (114) | | | (5,351) | | | 771 | |
Net loss | | $ | (133,657) | | $ | (33,580) | | $ | (187,691) | | $ | (146,372) | |
| | | | | | | | | |||||
Basic and diluted net loss per share | | $ | (2.32) | | $ | (0.60) | | $ | (3.28) | | $ | (2.77) | |
| | | | | | | | | |||||
Weighted-average shares outstanding used to compute basic and diluted net loss per share | | | 57,506 | | | 55,584 | | | 57,190 | | | 52,755 | |
21
| FEBRUARY 17, 2026 |
GAAP Balance Sheet
GLAUKOS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except par values)
| | December 31, | | December 31, | | ||
| | 2025 | | 2024 | | ||
| | (unaudited) | | | | ||
Assets | | | | | | |
|
Current assets: | | | | | | ||
Cash and cash equivalents | | $ | 90,813 | | $ | 169,626 | |
Short-term investments | | | 187,947 | | | 149,289 | |
Accounts receivable, net | | | 108,608 | | | 60,744 | |
Inventory | | | 63,564 | | | 57,678 | |
Prepaid expenses and other current assets | | | 24,052 | | | 12,455 | |
Total current assets | | | 474,984 | | | 449,792 | |
Restricted cash | | | 3,834 | | | 4,733 | |
Property and equipment, net | | | 113,253 | | | 97,867 | |
Operating lease right-of-use asset | | | 31,527 | | | 30,254 | |
Finance lease right-of-use asset | | | 39,404 | | | 41,816 | |
Intangible assets, net | | | 141,916 | | | 263,445 | |
Goodwill | | | 66,710 | | | 66,134 | |
Deposits and other assets | | | 21,859 | | | 20,715 | |
Total assets | | $ | 893,487 | | $ | 974,756 | |
| | | | | |||
Liabilities and stockholders' equity | | | | | | ||
Current liabilities: | | | | | | ||
Accounts payable | | $ | 24,624 | | $ | 13,026 | |
Accrued liabilities | | | 76,651 | | | 62,099 | |
Total current liabilities | | | 101,275 | | | 75,125 | |
Operating lease liability | | | 35,767 | | | 33,936 | |
Finance lease liability | | | 68,109 | | | 69,463 | |
Deferred tax liability, net | | | 441 | | | 6,928 | |
Other liabilities | | | 31,740 | | | 22,373 | |
Total liabilities | | | 237,332 | | | 207,825 | |
| | | | | |||
Stockholders' equity: | | | | | | ||
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding as of December, 2025 and December 31, 2024 | | | — | | | — | |
Common stock, $0.001 par value; 150,000 shares authorized; 57,539 and 56,472 shares issued and 57,511 and 56,544 shares outstanding at December 31, 2025 and December 31, 2024, respectively | | | 58 | | | 56 | |
Additional paid-in capital | | | 1,586,056 | | | 1,509,831 | |
Accumulated other comprehensive income | | | 3,303 | | | 2,615 | |
Accumulated deficit | | | (933,130) | | | (745,439) | |
Less treasury stock (28 shares as of December 31, 2025 and December 31, 2024) | | | (132) | | | (132) | |
Total stockholders' equity | | | 656,155 | | | 766,931 | |
Total liabilities and stockholders' equity | | $ | 893,487 | | $ | 974,756 | |
22
| FEBRUARY 17, 2026 |
Primary GAAP to Non-GAAP Reconciliations
GLAUKOS CORPORATION
GAAP to Non-GAAP Reconciliations
(in thousands, except per share amounts and percentage data)
(unaudited)
| | Q4 2025 | | Q4 2024 | | ||||||||||||||
| | GAAP | | | Adjustments | | Non-GAAP | | GAAP | | Adjustments | | Non-GAAP |
| |||||
| | | | | | | | | | | | | |||||||
Cost of sales | | $ | 31,771 | | $ | (10,452) | (a)(b)(c) | $ | 21,319 | | $ | 28,635 | | $ | (9,972) | (a)(c) | $ | 18,663 | |
| | | | | | | | | | | | | |||||||
Impairment of intangible asset | | $ | 112,867 | | $ | (112,867) | (d) | $ | — | | $ | — | | $ | — | | $ | — | |
| | | | | | | | | | | | | |||||||
Gross Margin | | | (1.1) | % | | 86.2 | % | | 85.1 | % | | 72.9 | % | | 9.4 | % | | 82.3 | % |
| | | | | | | | | | | | | |||||||
Operating expenses: | | | | | | | | | | | | | | ||||||
Selling, general and administrative | | $ | 94,700 | | $ | (187) | (e) | $ | 94,513 | | $ | 69,003 | | $ | (411) | (f) | $ | 68,592 | |
Loss from operations | | $ | (139,868) | | $ | 123,506 | | $ | (16,362) | | $ | (28,666) | | $ | 10,383 | | $ | (18,283) | |
| | | | | | | | | | | | | |||||||
Non-operating (expense) income: | | | | | | | | | | | | | | ||||||
Other (expense) income, net | | $ | (1,314) | | $ | — | | $ | (1,314) | | $ | (5,950) | | $ | 951 | (g) | $ | (4,999) | |
| | | | | | | | | | | | | |||||||
Income tax (benefit) provision | | $ | (6,159) | | $ | 6,204 | (h) | $ | 45 | | | (114) | | $ | — | | $ | (114) | |
| | | | | | | | | | | | | |||||||
Net loss | | $ | (133,657) | | $ | 117,302 | (i) | $ | (16,355) | | $ | (33,580) | | $ | 11,334 | (i) | $ | (22,246) | |
Basic and diluted net loss per share | | $ | (2.32) | | $ | 2.04 | | $ | (0.28) | | $ | (0.60) | | $ | 0.20 | | $ | (0.40) | |
(a) | Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $8.6 million in Q4 2025 and $5.5 million in Q4 2024. |
(b) | Mobius acquisition-related amortization expense of developed intellectual property of $0.5 million. |
(c) | Inventory write-down charges associated with the transition from Photrexa to Epioxa of $1.3 million in Q4 2025 and product line optimizations of $4.4 million in Q4 2024. |
(d) | Impairment of intangible asset associated with the transition from Photrexa to Epioxa. |
(e) | Mobius contingent consideration fair value adjustment. |
(f) | Avedro acquisition-related amortization expense of customer relationship intangible assets of $0.4 million. |
(g) | Remeasurement loss on derivative asset and direct transaction costs associated with the capped call unwind agreements. |
(h) | Tax effect from conversion of Avedro acquisition developed technology intangible asset from indefinite-lived to finite-lived. |
(i) | Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2025 and 2024. |
23
| FEBRUARY 17, 2026 |
Primary GAAP to Non-GAAP Reconciliations
GLAUKOS CORPORATION
GAAP to Non-GAAP Reconciliations
(in thousands, except per share amounts and percentage data)
(unaudited)
| | Full Year 2025 | | Full Year 2024 | | ||||||||||||||
| GAAP | | Adjustments | | Non-GAAP | | GAAP | | Adjustments | | Non-GAAP |
| |||||||
| | | | | | | | | | | | | |||||||
Cost of sales | | $ | 111,814 | | $ | (29,049) | (a)(b)(c)(d) | $ | 82,765 | | $ | 94,027 | | $ | (26,541) | (a)(d) | $ | 67,486 | |
| | | | | | | | | | | | | |||||||
Impairment of intangible asset | | $ | 112,867 | | $ | (112,867) | (e) | $ | — | | | | | ||||||
| | | | | | | | | | | | | |||||||
Gross Margin | | | 55.7 | % | | 28.0 | % | | 83.7 | % | | 75.5 | % | | 6.9 | % | | 82.4 | % |
| | | | | | | | | | | | | |||||||
Operating expenses: | | | | | | | | | | | | | | ||||||
Selling, general and administrative | | $ | 331,747 | | $ | (239) | (f) | $ | 331,508 | | $ | 261,166 | | $ | (2,526) | (g) | $ | 258,640 | |
| | | | | | | | | | | | | | | | | | | |
Loss from operations | | $ | (199,600) | | $ | 142,155 | | $ | (57,445) | | $ | (122,366) | | $ | 29,067 | | $ | (93,299) | |
| | | | | | | | | | | | | |||||||
Non-operating expense: | | | | | | | | | | | | | | | | | | | |
Charges associated with convertible senior notes | | $ | — | | $ | — | | $ | — | | $ | (18,012) | | $ | 18,012 | (h) | $ | — | |
| | | | | | | | | | | | | | | | | | | |
Other income (expense), net | | $ | 479 | | $ | — | | $ | 479 | | $ | (6,288) | | $ | 951 | (i) | $ | (5,337) | |
| | | | | | | | | | | | | | | | | | | |
Income tax (benefit) provision | | $ | (5,351) | | $ | 6,204 | (j) | $ | 853 | | $ | 771 | | $ | — | | $ | 771 | |
| | | | | | | | | | | | | | | | | | | |
Net loss | | $ | (187,691) | | $ | 135,951 | (k) | $ | (51,740) | | $ | (146,372) | | $ | 48,030 | (k) | $ | (98,342) | |
| | | | | | | | | | | | | | | | | | | |
Basic and diluted net loss per share | | $ | (3.28) | | $ | 2.38 | | $ | (0.90) | | $ | (2.77) | | $ | 0.91 | | $ | (1.86) | |
(a) | Cost of sales adjustment related to amortization of developed technology intangible assets associated with the acquisition of Avedro, Inc. (Avedro) of $25.2 million in 2025 and $22.1 million in 2024. |
(b) | Mobius acquisition-related amortization expense of developed intellectual property of $1.2 million. |
(c) | Non-recurring, non-cash charge related to the write-down of certain inventory of $1.3 million. |
(d) | Inventory write-down charges associated with the transition from Photrexa to Epioxa of $1.3 million in 2025 and product line optimizations of $4.4 million in 2024. |
(e) | Impairment of intangible asset associated with the transition from Photrexa to Epioxa. |
(f) | Mobius acquisition-related transaction expense of $0.3 million and contingent consideration fair value adjustment of ($0.1) million. |
(g) | Avedro acquisition-related amortization expense of customer relationship intangible assets. |
(h) | Expenses associated with the exchange of convertible senior notes, consisting of a non-cash inducement charge of $17.4 million and direct transaction costs of $0.6 million. |
(i) | Remeasurement loss on derivative asset and direct transaction costs associated with the capped call unwind agreements |
(j) | Tax effect from conversion of Avedro acquisition developed technology intangible asset from indefinite-lived to finite-lived. |
(k) | Includes total tax effect for non-GAAP pre-tax adjustments. For non-GAAP adjustments associated with the U.S., the tax effect is $0 given the Company's U.S. taxable loss positions in both 2025 and 2024. |
24
| FEBRUARY 17, 2026 |
Additional GAAP to Non-GAAP Reconciliations
Reported Sales vs. Prior Periods (in thousands) | ||||||||||||||||||||||
| | | | | | | | | | | Year-over-Year Percent Change | Quarter-over-Quarter Percent Change | ||||||||||
| | 4Q 2025 | | 4Q 2024 | | 3Q 2025 | | Reported | | Operations (1) | | Currency (2) | | Reported | | Operations (1) | | Currency (2) |
| |||
| | | | | | | | | | | | | | | | | | | | | | |
International Glaucoma | | $ | 32,779 | | $ | 27,869 | | $ | 29,443 |
| 17.6 | % | 13.1 | % | 4.5 | % | 11.3 | % | 12.7 | % | (1.4) | % |
| | | | | | | | | | | | | | | | | | | | | | |
Total Net Sales | | $ | 143,121 | | $ | 105,499 | | $ | 133,537 |
| 35.7 | % | 34.5 | % | 1.2 | % | 7.2 | % | 7.5 | % | (0.3) | % |
(1) Operational growth excludes the effect of translational currency
(2) Calculated by converting the current period numbers using the prior period’s average foreign exchange rates
Reported Sales vs. Prior Periods (in thousands) | |||||||||||||
| | | | | | | | Year-over-Year Percent Change | |||||
| | 2025 |
| 2024 |
| Reported |
| Operations (1) |
| Currency (2) | | ||
| | | | | | | | | | | | | |
International Glaucoma | | $ | 122,482 | | $ | 103,705 |
| 18.1 | % | 16.0 | % | 2.1 | % |
| | | | | | | | | | | | | |
Total Net Sales | | $ | 507,442 | | $ | 383,481 |
| 32.3 | % | 31.7 | % | 0.6 | % |
(1) Operational growth excludes the effect of translational currency
(2) Calculated by converting the current period numbers using the prior period’s average foreign exchange rates
For Non-GAAP disclosures associated with the company’s past quarterly results, included with respect to the sequential comparisons included herein, please see reconciliations here.
25
FAQ
How did Glaukos (GKOS) perform financially in Q4 2025?
What were Glaukos’ full-year 2025 results and profitability trends?
What guidance did Glaukos (GKOS) provide for 2026 revenue?
How strong is Glaukos’ balance sheet at the end of 2025?
What impact did the impairment charge have on Glaukos’ 2025 results?
How are Glaukos’ non-GAAP margins and expenses trending?
Filing Exhibits & Attachments
5 documentsPress Releases
